8 results on '"Bogorodskaya EM"'
Search Results
2. Emergency surgical care for patients with COVID-19 and tuberculosis coinfection at multispecialty hospital
- Author
-
Reshetnikov, MN, primary, Plotkin, DV, additional, Zuban, ON, additional, and Bogorodskaya, EM, additional
- Published
- 2021
- Full Text
- View/download PDF
3. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020
- Author
-
Migliori, GB, Thong, PM, Akkerman, O, Alffenaar, J-W, Alvarez-Navascues, F, Assao-Neino, MM, Bernard, PV, Biala, JS, Blanc, F-X, Bogorodskaya, EM, Borisov, S, Buonsenso, D, Calnan, M, Castellotti, PF, Centis, R, Chakaya, JM, Cho, J-G, Codecasa, LR, D'Ambrosio, L, Denholm, J, Enwerem, M, Ferrarese, M, Galvao, T, Garcia-Clemente, M, Garcia-Garcia, J-M, Gualano, G, Gullon-Blanco, JA, Inwentarz, S, Ippolito, G, Kunst, H, Maryandyshev, A, Melazzini, M, de Queiroz Mello, FC, Munoz-Torrico, M, Njungfiyini, PB, Palmero, DJ, Palmieri, F, Piccioni, P, Piubello, A, Rendon, A, Sabri, J, Saporiti, M, Scognamiglio, P, Sharma, S, Silva, DR, Souleymane, MB, Spanevello, A, Tabernero, E, Tadolini, M, Tchangou, ME, Thornton, ABY, Tiberi, S, Udwadia, ZF, Sotgiu, G, Ong, CWM, Goletti, D, Migliori, GB, Thong, PM, Akkerman, O, Alffenaar, J-W, Alvarez-Navascues, F, Assao-Neino, MM, Bernard, PV, Biala, JS, Blanc, F-X, Bogorodskaya, EM, Borisov, S, Buonsenso, D, Calnan, M, Castellotti, PF, Centis, R, Chakaya, JM, Cho, J-G, Codecasa, LR, D'Ambrosio, L, Denholm, J, Enwerem, M, Ferrarese, M, Galvao, T, Garcia-Clemente, M, Garcia-Garcia, J-M, Gualano, G, Gullon-Blanco, JA, Inwentarz, S, Ippolito, G, Kunst, H, Maryandyshev, A, Melazzini, M, de Queiroz Mello, FC, Munoz-Torrico, M, Njungfiyini, PB, Palmero, DJ, Palmieri, F, Piccioni, P, Piubello, A, Rendon, A, Sabri, J, Saporiti, M, Scognamiglio, P, Sharma, S, Silva, DR, Souleymane, MB, Spanevello, A, Tabernero, E, Tadolini, M, Tchangou, ME, Thornton, ABY, Tiberi, S, Udwadia, ZF, Sotgiu, G, Ong, CWM, and Goletti, D
- Abstract
Coronavirus disease has disrupted tuberculosis services globally. Data from 33 centers in 16 countries on 5 continents showed that attendance at tuberculosis centers was lower during the first 4 months of the pandemic in 2020 than for the same period in 2019. Resources are needed to ensure tuberculosis care continuity during the pandemic.
- Published
- 2020
4. IMPACT OF HIV INFECTION ON THE STRUCTURE OF NEW TUBERCULOSIS CASES DETECTED IN THE CITY OF MOSCOW
- Author
-
E. A. Kotova, Bogorodskaya Em, Sergey Borisov, M. V. Sinitsyn, and Evgeny Belilovsky
- Subjects
hiv infection ,Pediatrics ,medicine.medical_specialty ,Tuberculosis ,RC705-779 ,business.industry ,Incidence (epidemiology) ,Significant part ,Human immunodeficiency virus (HIV) ,General Medicine ,medicine.disease ,medicine.disease_cause ,monitoring ,Diseases of the respiratory system ,tuberculosis ,Pulmonary tuberculosis ,Immunology ,Medicine ,business ,Lung tissue ,Hiv transmission ,Tuberculosis incidence - Abstract
The article presents the impact of HIV transmission on the incidence of tuberculosis in a big city according to the data of the tuberculosis monitoring register for 2015-2016. The findings demonstrated that among tuberculosis patients with concurrent HIV infection, the following typical characteristics were frequent versus other tuberculosis patients: patients permanently residing in the city, the age of 31-40 years old, men, the unemployed, with no destruction of lung tissue, with disseminated form of pulmonary tuberculosis, and experience of incarceration. The significant part of such patients had lesions in chest lymph nodes. Despite the overall reduction in the part of HIV positive cases among tuberculosis cases in Moscow, the obtained data highlight the significant impact of concurrent HIV infection on tuberculosis incidence and structure of new cases of tuberculosis.
- Published
- 2017
5. [The influence of comorbidities on treatment outcomes in patients with tuberculosis].
- Author
-
Ivanova DA, Belilovskiy EM, Bogorodskaya EM, Reshetnikov MN, Plotkin DV, and Avdentova VB
- Subjects
- Humans, Male, Female, Retrospective Studies, Adult, Middle Aged, Risk Factors, Moscow epidemiology, Antitubercular Agents therapeutic use, Treatment Outcome, Comorbidity, Tuberculosis epidemiology, HIV Infections epidemiology, HIV Infections drug therapy, HIV Infections complications
- Abstract
Aim: To study the association of comorbidities and treatment outcomes in tuberculosis (TB) patients., Materials and Methods: A retrospective study includes all TB patients aged 18 years and older registered for treatment in Moscow in period 2021 the end of the 3rd quarter of 2022 using data of regional epidemiological TB monitoring system, a total of 3039 patients. The frequency and spectrum of comorbidities, its impact on the risk of adverse treatment outcome (ATO) and mortality using univariate and regression analysis were assessed., Results: Comorbidities were identified in 1528 (50.3%) patients (95% confidence interval - CI 48.5-52.1); HIV infection (18.0%), chronic nonspecific lung disease (9.6%) and cardiovascular disease (8.2%) were predominant. The presence of comorbid pathology increased the odds of uneffective treatment (odds ratio - OR 2.56, 95% CI 2.22-3.03) and death (OR 2.45, 95% СI 1.67-3.59). Independent risk factors for ATO were HIV infection (OR 4.10, 95% CI 3.36-5.10), substance use (OR 2.57, 95% CI 1.70-3.66), chronic nonspecific lung disease (OR 1.39, 95% CI 1.04-1.88), diabetes mellitus (OR 1.69, 95% CI 1.15-2.48), liver pathology (OR 2.10, 95% CI 1.46-3.03), mental illness (OR 2.01, 95% CI 1.32-3.06). The death rate was 13.4%; the most significant predictors of mortality were HIV infection (OR 3.89, 95% CI 2.42-6.22) and liver disease (OR 1.90, 95% CI 1.27-2.82). A comorbidome model was constructed to assess the importance of different comorbidities for patient prognosis., Conclusion: The presence of comorbidity (predominantly HIV infection and liver disease) is a significant risk factor for ATO and mortality in TB patients, which should be taken into account when organizing and providing TB care to comorbid patients.
- Published
- 2024
- Full Text
- View/download PDF
6. Research of Russian physicians' opinions on tuberculosis pharmacogenetics.
- Author
-
Kantemirova BI, Bogorodskaya EM, Poptsova MS, Sychev DA, Tsimbal EA, and Stepanova NA
- Subjects
- Humans, Pharmacogenetics, Academies and Institutes, Russia, Physicians, Tuberculosis drug therapy
- Abstract
Background: There is currently no widespread implementation of pharmacogenetic testing (PGx) methods in the practice of phthisiology service., Objective: The aim of this study is to determine how informed and prepared phthisiologists, residents, and postgraduate students of the Russian Medical Academy of Continuing Professional Education (RMACPE, Moscow) use PGx techniques in their work to improve treatment safety, predict the occurrence of adverse reactions (ADRs), and personalize therapy., Methods: A survey was conducted among phthisiologists (n = 314) living in different regions of the Russian Federation and studying at RMACPE, such as residents and post-graduate students (n = 185). The survey was developed on the Testograf.ru web platform and had 25 questions for physicians and 22 for residents and post-graduate students., Results: More than 50% of respondents are ready to use PGx in clinical practice and thus are aware of the method's possibilities. At the same time only a small part of participants were aware of the pharmgkb.org resource. The absence of PGx in clinical guidelines and treatment standards, according to 50.95% of phthisiologists and 55.13% of students of RMACPE, the absence of large-scale randomized clinical trials, according to 37.26% of phthisiologists and 43.33% of students, and the lack of physician knowledge on PGx, according to 41.08% of phthisiologists and 57.83% of students, are all factors that prevent the implementation of PGx in Russia., Conclusion: According to the survey, the overwhelming majority of participants recognize the importance of PGx and are willing to use the method in practice. However, there is a low level of awareness among all respondents about the possibilities of PGx and the pharmgkb.org resource. The implementation of this service could significantly increase patient compliance, lower ADRs, and enhance anti-tuberculosis (TB) therapy quality.
- Published
- 2024
- Full Text
- View/download PDF
7. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020.
- Author
-
Migliori GB, Thong PM, Akkerman O, Alffenaar JW, Álvarez-Navascués F, Assao-Neino MM, Bernard PV, Biala JS, Blanc FX, Bogorodskaya EM, Borisov S, Buonsenso D, Calnan M, Castellotti PF, Centis R, Chakaya JM, Cho JG, Codecasa LR, D'Ambrosio L, Denholm J, Enwerem M, Ferrarese M, Galvão T, García-Clemente M, García-García JM, Gualano G, Gullón-Blanco JA, Inwentarz S, Ippolito G, Kunst H, Maryandyshev A, Melazzini M, de Queiroz Mello FC, Muñoz-Torrico M, Njungfiyini PB, Palmero DJ, Palmieri F, Piccioni P, Piubello A, Rendon A, Sabriá J, Saporiti M, Scognamiglio P, Sharma S, Silva DR, Souleymane MB, Spanevello A, Tabernero E, Tadolini M, Tchangou ME, Thornton ABY, Tiberi S, Udwadia ZF, Sotgiu G, Ong CWM, and Goletti D
- Subjects
- Betacoronavirus, COVID-19, Humans, Pandemics, SARS-CoV-2, Tuberculosis epidemiology, Continuity of Patient Care trends, Coronavirus Infections epidemiology, Facilities and Services Utilization trends, Global Health trends, Pneumonia, Viral epidemiology, Tuberculosis therapy
- Abstract
Coronavirus disease has disrupted tuberculosis services globally. Data from 33 centers in 16 countries on 5 continents showed that attendance at tuberculosis centers was lower during the first 4 months of the pandemic in 2020 than for the same period in 2019. Resources are needed to ensure tuberculosis care continuity during the pandemic.
- Published
- 2020
- Full Text
- View/download PDF
8. A Comparison of the Sensititre MycoTB Plate, the Bactec MGIT 960, and a Microarray-Based Molecular Assay for the Detection of Drug Resistance in Clinical Mycobacterium tuberculosis Isolates in Moscow, Russia.
- Author
-
Nosova EY, Zimenkov DV, Khakhalina AA, Isakova AI, Krylova LY, Makarova MV, Galkina KY, Krasnova MA, Safonova SG, Litvinov VI, Gryadunov DA, and Bogorodskaya EM
- Subjects
- Antitubercular Agents therapeutic use, Genotype, Humans, Moscow, Mutation, Mycobacterium tuberculosis isolation & purification, Mycobacterium tuberculosis physiology, Phenotype, Tuberculosis drug therapy, Antitubercular Agents pharmacology, Drug Resistance, Bacterial genetics, Microbial Sensitivity Tests methods, Mycobacterium tuberculosis drug effects, Mycobacterium tuberculosis genetics, Oligonucleotide Array Sequence Analysis
- Abstract
Background: The goal of this study was to compare the consistency of three assays for the determination of the drug resistance of Mycobacterium tuberculosis (MTB) strains with various resistance profiles isolated from the Moscow region., Methods: A total of 144 MTB clinical isolates with a strong bias toward drug resistance were examined using Bactec MGIT 960, Sensititre MycoTB, and a microarray-based molecular assay TB-TEST to detect substitutions in the rpoB, katG, inhA, ahpC, gyrA, gyrB, rrs, eis, and embB genes that are associated with resistance to rifampin, isoniazid, fluoroquinolones, second-line injectable drugs and ethambutol., Results: The average correlation for the identification of resistant and susceptible isolates using the three methods was approximately 94%. An association of mutations detected with variable resistance levels was shown. We propose a change in the breakpoint minimal inhibitory concentration for kanamycin to less than 5 μg/ml in the Sensititre MycoTB system. A pairwise comparison of the minimal inhibitory concentrations (MICs) of two different drugs revealed an increased correlation in the first-line drug group and a partial correlation in the second-line drug group, reflecting the history of the preferential simultaneous use of drugs from these groups. An increased correlation with the MICs was also observed for drugs sharing common resistance mechanisms., Conclusions: The quantitative measures of phenotypic drug resistance produced by the Sensititre MycoTB and the timely detection of mutations using the TB-TEST assay provide guidance for clinicians for the choice of the appropriate drug regimen., Competing Interests: DG and DZ are from a group of developers that invented the TB-TEST microarray assay and are the only authors of Russian patent #2562866, filed by the Engelhardt Institute of Molecular Biology (EIMB). Currently, the TB-TEST kit is produced and sold by the EIMB spin-off company Biochip-IMB, LLC. DG and DZ earned royalties from patent licensing (in 2015 these royalties comprised approximately $100 US dollars per person). DG and DZ are not employees of the Biochip-IMB company and have no direct commercial or financial relationship with this company. There are not any further patents, products in development or marketed products to declare. Therefore, we declare that this circumstance does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. All other authors have declared that no competing interests exist.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.